ALDH1A1 Monoclonal Antibody

Aldehyde dehydrogenase 1 (ALDH1) is an NADP+-dependent member of the aldehyde dehydrogenase superfamily that metabolizes exogenously produced aldehydes to alleviate aldehyde stress.{66276} ALDH1 is expressed as three isozymes, ALDH1A1, ALDH1A2, and ALDH1A3, of which, ALDH1A1 shares greater than 70% sequence homology with ALDH1A2 and ALDH1A3. ALDH1A1 is a cytosolic homotetramer, with each monomer composed of a catalytic domain, an NAD-binding domain, and an oligomerization domain that is widely expressed in brain, liver, kidneys, adipose tissue, retina, and lens. It catalyzes the oxidation of retinaldehyde to retinoic acid, a transcriptional regulator essential for normal cell growth and differentiation.{66276,66277} Tumoral levels of ALDH1A1 are increased and associated with poor prognosis in patients with high clinical stages of nasopharyngeal carcinomas.{66277} Levels of ALDH1A1 are positively correlated with disease severity in postmortem brain tissue from patients with Alzheimer’s disease.{66278} ALDH1A1-positive nigrostriatal dopaminergic neurons (DANs) are decreased compared with the number of ALDH1A1-negative nigrostriatal DANs in postmortem brain tissue from patients with Parkinson’s disease.{66279} Cayman’s ALDH1A1 Monoclonal Antibody (Clone 5G9E6C9) can be used for ELISA, flow cytometry (FC), immunocytochemistry (ICC), immunofluorescence (IF), and Western blot (WB) applications.